1. A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells
- Author
-
Rafael Rosell, Teresa Moran, Miguel Angel Molina-Vila, Noemi Reguart, Miquel Taron, Maria Pérez-Cano, Clara Mayo, Esther Carrasco, Jose Luis Mate, Monica Botia, Eva Castellà, Carlota Costa, Jordi Bertran-Alamillo, Cristina Queralt, Mireia Tomàs, Anna Pradas, and Mariona Llatjós
- Subjects
Male ,erlotinib ,Lung Neoplasms ,medicine.disease_cause ,Polymerase Chain Reaction ,T790M ,law.invention ,Exon ,Non-small cell lung cancer ,law ,Carcinoma, Non-Small-Cell Lung ,Prospective Studies ,Epidermal growth factor receptor ,Polymerase chain reaction ,Aged, 80 and over ,Mutation ,biology ,DNA, Neoplasm ,Exons ,Middle Aged ,Prognosis ,ErbB Receptors ,Survival Rate ,Oncology ,Female ,Erlotinib ,medicine.drug ,Adult ,Pulmonary and Respiratory Medicine ,Adenocarcinoma ,Cytologic samples ,Sensitivity and Specificity ,Erlotinib Hydrochloride ,medicine ,Humans ,Lung cancer ,Protein Kinase Inhibitors ,Aged ,Neoplasm Staging ,business.industry ,medicine.disease ,EGFR mutations ,Molecular biology ,respiratory tract diseases ,Cancer cell ,Quinazolines ,biology.protein ,business - Abstract
Background Detection of epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer (NSCLC) patients has relied on DNA purification from biopsies, amplification, and sequencing. However, the number of tumor cells in a sample is often insufficient for EGFR assessment. Methods We prospectively screened 1380 NSCLC patients for EGFR mutations but found that 268 were not evaluable because of insufficient tumor tissue. We therefore developed and validated a method of detecting EGFR mutations in these samples. Tumor cells were microdissected into polymerase chain reaction buffer and amplified. EGFR mutations were detected by length analysis of fluorescently labeled polymerase chain reaction products and TaqMan assay. Results We determined EGFR status in 217 (81%) of the 268 primary NSCLC samples not evaluable in our original study—fresh and paraffin-embedded with less than 150 cells. Exon 19 deletions were detected in 11.5% of patients and exon 21 L858R mutations in 5.5%. In addition, the exon 20 T790M mutation was detected in 6 of 15 (40%) patients at the time of progression to erlotinib. The primary, sensitive mutation was present in all tumor cells, whereas the T790M mutation was absent in some groups. Conclusions The method presented here eliminates the need for DNA purification and allows for detection of EGFR mutations in samples containing as few as eight cancer cells.
- Published
- 2008